side effects of semaglutide shots for diabetes and obesity treatment 🚨 OZEMPIC USERS – KNOW

Open communication with your healthcare team enables timely investigation and appropriate management adjustments

Report any suspected side effects via the MHRA Yellow Card Scheme, particularly important for investigational medicines

M., Morsink, L

2025 saw a bidding war between Pfizer and Novo Nordisk for Metsera and its portfolio of obesity agents, which was ultimately won by Pfizer for up to $10 billion

The FDA's stated reasoning is that there's no clinical need for outsourcing facilities to compound these drugs from bulk substances when FDA-approved versions exist

Coauthors of the study include Kamika Reynolds and Kimberly OMalley of the Institute for Health and Jason Roy of the Rutgers School of Public Health.